Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)

February 27, 2026 | Comments Off on Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)

Lung Cancer 2026 March [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc…

Artificial Intelligence in Pleural Diseases: Current Applications and Next Steps

February 26, 2026 | Comments Off on Artificial Intelligence in Pleural Diseases: Current Applications and Next Steps

Thoracic Research and Practice 2026 January 30 [Link] Ferhan Karataş, Öner Dikensoy Abstract Pleural diseases pose a significant burden on healthcare systems due to diagnostic challenges and high costs. Artificial…

Cytoreductive surgery and HIPEC for multicystic peritoneal mesothelioma: therapeutic approach in a rare benign neoplasm

February 25, 2026 | Comments Off on Cytoreductive surgery and HIPEC for multicystic peritoneal mesothelioma: therapeutic approach in a rare benign neoplasm

Journal of Surgical Case Reports 2026 January 8 [Link] Goran Aleksandrić, Nemanja Trifunović, Jovana Trifunović, Sara Filipović, Nebojša Mitrović Abstract Multicystic peritoneal mesothelioma (MCPM) is an uncommon tumor of mesothelial…

Real-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China

February 24, 2026 | Comments Off on Real-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China

Translational Lung Cancer Research 2025 December 31 [Link] Binhe Tian, Boyu Sun, Zixiang Zhou, Shuman Kuang, Jiongyuan Li, Weixuan Pan, Zhe Zhu, Xiaoyan Si, Li Zhang, Jun Liu, Juhong Shi,…

Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations

February 23, 2026 | Comments Off on Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations

Lung Cancer 2026 February [Link] Kathleen Zwijsen, Ellen Heirwegh, Eline Schillebeeckx, Elly Marcq, Adrian Covaci, Ken Op de Beeck, Jan P van Meerbeeck, Jo Raskin, Annelies Janssens, Annemiek Snoeckx, Kevin…

The Accuracy of Video-Assisted Thoracic Surgery Pleural Biopsy in Patients with Suspected Diffuse Pleural Mesothelioma: A Real-Life Study

February 20, 2026 | Comments Off on The Accuracy of Video-Assisted Thoracic Surgery Pleural Biopsy in Patients with Suspected Diffuse Pleural Mesothelioma: A Real-Life Study

Journal of Clinical Medicine 2025 December 20 [Link] Ludovica Balsamo, Enrica Migliore, Eleonora Della Beffa, Luisa Delsedime, Paolo Olivo Lausi, Daniela Di Cuonzo, Filippo Lococo, Paraskevas Lyberis, Dario Mirabelli, Mauro…

Prognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma

February 19, 2026 | Comments Off on Prognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma

Journal of Nuclear Medicine 2026 January 22 [Link] Lukas Kessler, Felix Schwaning, Martin Metzenmacher, Kim M Pabst, Marcel Opitz, Marcel Wiesweg, Clemens Aigner, Till Ploenes, Servet Bölükbas, Fabian Doerr, Martin…

Real-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China

February 18, 2026 | Comments Off on Real-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China

Translational Lung Cancer Research 2025 December 31 [Link] Binhe Tian, Boyu Sun, Zixiang Zhou, Shuman Kuang, Jiongyuan Li, Weixuan Pan, Zhe Zhu, Xiaoyan Si, Li Zhang, Jun Liu, Juhong Shi,…

BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities

February 17, 2026 | Comments Off on BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities

Oncogene 2026 February [Link] Jasper H L T van Genugten, Dean A Fennell, Paul Baas Abstract Mesothelioma is an aggressive cancer that is often characterized by loss of the BRCA1-associated…

BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities

February 16, 2026 | Comments Off on BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities

Oncogene 2026 February [Link] Jasper H L T van Genugten, Dean A Fennell, Paul Baas Abstract Mesothelioma is an aggressive cancer that is often characterized by loss of the BRCA1-associated…

Categories